In AML patients, donor-derived CD8 + T-cells modified to express WT1-specific TCRs have already been tested to prevent relapse post hematopoietic stem cell transplantation (HSCT), and promising initial responses have been obtained [11, 12]. Here, CD8A is linked to acute myeloid leukemia.